Research programme: halimide analogues - Nereus

Drug Profile

Research programme: halimide analogues - Nereus

Alternative Names: NPI 2350; NPI 2362; NPI 2386; NPI 2460

Latest Information Update: 16 Oct 2007

Price : $50

At a glance

  • Originator Kyoto University; University of California System
  • Developer Nereus Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 23 Jul 2003 Data presented at the 94th Annual Meeting of the American Association for Cancer Research (AACR-2003) have been added to the Cancer pharmacodynamics section
  • 16 Oct 2001 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top